ArthroCare Corporation (ArthroCare) is a medical device company. ArthroCare develops and manufactures surgical devices, instruments, and implants. Its devices enable surgical procedures and enable new minimally invasive procedures. Many of ArthroCare's devices use its Coblation technology. This technology dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology, including its OPUS line of fixation products, as well as re-usable surgical instruments. ArthroCare's two core product consists of sports medicine and ear, nose, and throat (ENT), as well as other areas, such as spine, wound care, urology and gynecology. It's Sports Medicine, ENT and other products are marketed and sold through two principal geographic distribution channels: Americas (North and South America) and International (all other geographies). In May 2014, Smith & Nephew PLC acquired the Company.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Health Care Equipment & Supplies
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:ARTC
- CUSIP: 04313610
- Web: N/A
- 50 Day Moving Avg: $3.00
- 200 Day Moving Avg: $4.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 30.57
- P/E Growth: 0
Frequently Asked Questions for ArthroCare (NASDAQ:ARTC)
What is ArthroCare's stock symbol?
ArthroCare trades on the NASDAQ under the ticker symbol "ARTC."
Who are some of ArthroCare's key competitors?
Some companies that are related to ArthroCare include Merck KGaA (MKGAY), Hospira (HSP), Omnicare (OCR), Health Net (HNT), WuXi PharmaTech (Cayman) (WX), Hanger (HGR), SIGA Technologies (SIGA), Nobilis Health Corp (HLTH), Verastem (VSTM), Palatin Technologies (PTN), KaloBios Pharmaceuticals (KBIO), AdCare Health Systems (ADK), Capricor Therapeutics (CAPR), 3SBio (SSRX), Alexza Pharmaceuticals (ALXA), Allergan plc (WPI), Allergan plc (ACT) and Allos Therapeutics (ALTH).
How do I buy ArthroCare stock?
Shares of ArthroCare can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ArthroCare stock cost?
One share of ArthroCare stock can currently be purchased for approximately $48.60.
Consensus Ratings for ArthroCare (NASDAQ:ARTC) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for ArthroCare (NASDAQ:ARTC)
(Data available from 5/26/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/23/2015||Needham & Company LLC||Reiterated Rating||Buy||N/A|
|8/7/2015||BTIG Research||Initiated Coverage||Buy||N/A|
Earnings History for ArthroCare (NASDAQ:ARTC)Earnings History by Quarter for ArthroCare (NASDAQ:ARTC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/2/2014||Q313||$0.35||$0.32||$96.00 million||$96.06 million||View||N/A|
|2/13/2014||Q213||$0.40||$0.30||$100.53 million||$101.70 million||View||N/A|
|8/5/2013||Q2 2013||$0.34||($0.27)||$93.67 million||$92.10 million||View||Listen|
|5/7/2013||Q1 2013||$0.37||$0.30||$94.41 million||$92.30 million||View||Listen|
|2/13/2013||Q4 2012||$0.37||$0.30||$93.78 million||$96.90 million||View||Listen|
Earnings Estimates for ArthroCare (NASDAQ:ARTC)
Current Year EPS Consensus Estimate: $1.51 EPS
Next Year EPS Consensus Estimate: $1.59 EPS
Dividend History for ArthroCare (NASDAQ:ARTC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ArthroCare (NASDAQ:ARTC)Insider Trades by Quarter for ArthroCare (NASDAQ:ARTC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/9/2014||Jean Woloszko||SVP||Sell||32,627||$45.67||$1,490,075.09|| |
|1/8/2014||Barbara Boyan||Director||Sell||10,000||$45.00||$450,000.00|| |
|1/8/2014||Bruce Prothro||SVP||Sell||33,478||$45.82||$1,533,961.96|| |
|1/6/2014||Bruce Prothro||SVP||Sell||6,167||$39.75||$245,138.25|| |
|12/19/2013||Barbara Boyan||Director||Sell||10,000||$40.00||$400,000.00|| |
|12/19/2013||Jean Woloszko||SVP||Sell||10,657||$39.98||$426,066.86|| |
|10/30/2013||Jean Woloszko||SVP||Sell||1,342||$37.95||$50,928.90|| |
|10/7/2013||James Pacek||SVP||Sell||2,500||$34.48||$86,200.00|| |
|6/18/2013||Bruce Prothro||SVP||Sell||2,512||$36.00||$90,432.00|| |
|5/24/2013||Peter Wilson||Director||Sell||10,000||$33.36||$333,600.00|| |
|11/13/2012||David Fitzgerald||Director||Sell||25,000||$31.34||$783,500.00|| |
|8/7/2012||James G Foster||Director||Sell||35,000||$28.81||$1,008,350.00|| |
Headline Trends for ArthroCare (NASDAQ:ARTC)
Latest Headlines for ArthroCare (NASDAQ:ARTC)
No headlines for this company have been tracked by MarketBeat.com
ArthroCare (ARTC) Chart for Friday, May, 26, 2017